INTRODUCTION {#sec1-1}
============

Acromegaly is a rare chronic disease, characterized by excessive production of growth hormone (GH). The total prevalence ranges between 2.8 and 13.7 cases per 100,000 people, and the annual incidence rates range between 0.2 and 1.1 cases per 100,000 people.\[[@ref1][@ref2]\] In the vast majority of cases, it occurs as a result of a somatotroph pituitary adenoma and a consequent overproduction of insulin-like growth factor I (IGF-I) by the liver and other tissues. Due to the subtle progress of the disease, diagnosis is frequently delayed for about 8--10 years after onset of clinical manifestations, which means that patients are rarely diagnosed before the age of 40.\[[@ref3][@ref4][@ref5][@ref6][@ref7][@ref8][@ref9]\] A vast number of clinical series have demonstrated that acromegaly is associated with increased morbidity and mortality, mainly due to cardiovascular (CV) complications.\[[@ref10][@ref11]\] GH and IGF-I excess result in arterial hypertension (HTN) in one-third of these patients. Acromegalic cardiomyopathy is one of the leading causes of death in patients with acromegaly.\[[@ref12]\] Choice of treatment should be individualized based on biochemical and radiological features, as well as the metabolic and CV risk profile of the patients.\[[@ref13][@ref14][@ref15][@ref16]\] In practice, when transsphenoidal surgery fails to control the disease or cannot be performed, the majority of endocrinologists prescribe first-generation somatostatin analogs (SSAs), for example, octreotide and lanreotide, as an initial medical treatment.\[[@ref17]\] To the best of our knowledge, five human somatostatin receptor (SSTR1, 2A and B, 3, 4, and 5) subtypes have been identified, and SSTR2 is the subtype expressed in more than 95% of somatotroph adenomas, followed by SSTR5, in approximately 85% of cases.\[[@ref16][@ref18]\] SSTR1 and SSTR3 are present in about 40% of adenomas.\[[@ref19][@ref20][@ref21]\] First-generation SSAs are considered SSTR2 specific. The biochemical response rate of these drugs is reported to be between 20% and 70%.\[[@ref19]\] There has been a belief that treatment with SSAs is successful in improving CV parameters, by means of their efficacy in the control of GH/IGF-I excess. However, the expression of somatostatin receptors type 1, 2, 4, and 5 on cardiac tissue and vascular bed raises the possibility of a direct effect of SSA on the heart and vessels.\[[@ref22][@ref23]\] In fact, based on a longitudinal study which evaluated different GH-lowering treatments, SSAs seemed to contribute to the improvement of echocardiographic parameters even in patients who had not achieved complete biochemical control of the disease.\[[@ref24]\] Likewise, in an open-label randomized study, despite an overall similar success rate, treatment with SSAs had beneficial effects on CV parameters which were though not obvious in surgically treated patients.\[[@ref22]\] Specifically, various studies reported that SSAs had a beneficial effect on blood pressure (BP),\[[@ref25][@ref26]\] heart rate (HR), systolic and diastolic function, exercise tolerance,\[[@ref22][@ref24][@ref25][@ref27][@ref28][@ref29][@ref30]\] reduced left ventricular mass, QT interval duration, and the rate of arrhythmias.\[[@ref31][@ref32]\] To the best of our knowledge, no head-to-head comparisons are available to analyze the efficacy of lanreotide and octreotide on the CV parameters except that Auriemma *et al*. showed that there was no significant difference in the effect of two drugs on BP.\[[@ref33]\] However, due to heterogeneity in the literature, different results were published. Furthermore, assessment with new imaging modalities such as cardiac magnetic resonance (CMR) imaging and speckle tracking echocardiography (STE) has been associated with contradictory results.\[[@ref34][@ref35]\] Therefore, by considering the widespread use of first-generation SSAs, our aim is to conduct a systematic review on available studies on the impact of these drugs on CV parameters.

MATERIALS AND METHODS {#sec1-2}
=====================

Database search {#sec2-1}
---------------

According to the medical liaison librarian\'s guide, a learning search strategy was created to identify studies. A literature search was conducted in MEDLINE (OVID), EMBase, Cochrane, and ISI Web of Science for citations published until April 30 2018. For this search, we established a Boolean search strategy using keywords related to "acromegaly," "Somatostatin analog" (lanreotide OR Sandostatin LAR Depot OR Sandostatin OR Somatuline Depot), and "cardiovascular diseases and parameters." We used MeSH terms in Medline and Cochrane and EM Tree terms in EMBase such as "Acromegaly," "cardiovascular parameters," and "cardiovascular diseases." We also used field search and truncation for more effective retrieval in aforesaid databases. For studies before June 2006, a hand searching was also performed in a meta-analysis by Maison *et al*.,\[[@ref30]\] which analyzed suitable articles until this date. The selected publications had to report at least one of the following outcome measures: HR, systolic BP (SBP), diastolic BP (DBP), interventricular septum diameter, left ventricle end-diastolic diameter (LVEDD), left ventricle mass (LVM), LVM index (per m^2^ of body surface area) (LVMi), left ventricle ejection fraction (EF), ratio of early to late mitral diastolic flow (E/A ratio), and left ventricle end diastolic volume (LVEDV). Each study was reviewed by 2 separate authors (M.H. and D.SH.) who independently screened abstracts and titles.

Inclusion and exclusion criteria {#sec2-2}
--------------------------------

Inclusion criteria were (1) articles published in English, (2) all studies except case reports or conference abstracts, (3) treatment with first generation SSAs, and (4) including CV endpoints. Exclusion criteria were (1) failure to compare CV parameters before treatment with posttreatment and (2) use an alternative treatment such as surgery during the study period.

Data extraction {#sec2-3}
---------------

Results from all databases entered the Endnote desktops (version 7.2), and copies were identified and deleted. All the titles were reviewed by one of the authors (M. H.), and nonrelevant items were identified and removed. The studies were screened by two authors (D.SH. and M.H.) using their abstract. The remaining item was examined for the full text of the articles and the entire text was added, and the articles were re-examined using the full text and reviewed by the two authors. Data were collected and include first author, year of publication, number of patients, drug, treatment duration, dosage, GH level before and after treatment, IGF-1 level before and after treatment, and changes in CV parameters \[[Table 1](#T1){ref-type="table"}\].

###### 

Characteristics of selected studies evaluating the effects of first-generation somatostatin analogs on the cardiovascular parameters

  Authors                          Year   Total patients (*n*)   Treatment        Duration (months)   Dose (mg)         GH before (μg/L)   GH after (μg/L)   IGF1 before (μg/L)   IGF1 after (μg/L)   Cardiac Imaging Modality   Result (s)
  -------------------------------- ------ ---------------------- ---------------- ------------------- ----------------- ------------------ ----------------- -------------------- ------------------- -------------------------- ---------------------------------------------
  Thuesen *et al*\[[@ref37]\]      1989   9                      Sandostatin      12                  0.6^b^            63±51              21±21             N/D                  N/D                 Echocardiography           HR↓, BP↓, LVMi↕
  Pereira *et al*\[[@ref38]\]      1991   5                      Sandostatin      6                   0.3^b^            22.4±9             4.3±23            N/D                  N/D                 Echocardiography           EF↓, LVEDD↕, LVMi↕, IVS↓, E/A↓
  Lim *et al*c\[[@ref39]\]         1992   10                     Sandostatin      2                   0.15^b^           19±4               N/D               481±49               N/D                 Echocardiography           HR↓, BP↕, LVEDD↕, IVS↓, LVMi↓
  Lim *et al*c\[[@ref39]\]         1992   6                      Sandostatin      2                   0.15^b^           28±9               N/D               584±53               N/D                 Echocardiography           HR↕, BP↕, LVEDD↕, IVS↕, LVMi↕
  Merola *et al*\[[@ref40]\]       1993   11                     Sandostatin      6                   0.1 ^b^           34±6.5             4.6±0.9           767±72.4             235±10.3            Echocardiography           HR↕, BP↕, EF↕, LVEDD↕, IVS↓, LVMi↓, E/A↑
  Tokgozoglu *et al*\[[@ref41]\]   1994   6                      Sandostatin      6                   0.3^b^            15.8±9             4±4               N/D                  N/D                 Echocardiography           HR↕, BP↕, EF↕, LVEDD↕
  Giustina *et al*\[[@ref42]\]     1995   10                     Sandostatin      0.033               0.15^b^           19±6               8±3               584±69               491±57              Echocardiography           HR↓, BP↕, EF↑, LVEDD↕, IVS↕, LVEDV↕
  Padayatty *et al*\[[@ref43]\]    1996   10                     Sandostatin      12                  0.3^b^            58±60              32±71             979±375              639±314             Echocardiography           HR↓, BP↕, EF↕
  Lombardi *et al*\[[@ref44]\]     1996   26                     Sandostatin      6                   0.15^b^           34±6.5             4.6±0.9           767.4±72             235±10              Echocardiography           EF↓, IVS↓, LVMi↓
  Hradec *et al*\[[@ref50]\]       1999   13                     Lanreotide PR    18                  30^d^             86±110             33±53             1222±249             746±403             Echocardiography           HR↕, BP↕, EF↕, LVEDD↓, IVS↓, LVMi↓, E/A↕
  Colao *et al*\[[@ref46]\]        1999   30                     Sandostatin      12                  0.15-0.3^b^       40.9±6             5.8±1.3           672.4±32             398.5±38            Echocardiography           HR↓, BP↕, EF↑
  Baldelli *et al*\[[@ref51]\]     1999   13                     Lanreotide PR    12                  30^d^             10.1±2.2           3.9±0.9           511±33               305.8±34            Echocardiography           BP↕, EF↕, LVEDD↕, IVS↓, LVEDV↓, LVMi↓, E/A↑
  Colao *et al*\[[@ref29]\]        2000   15                     Octreotide LAR   6                   20^e^             94±24.9            12.9±2.7          757.8±66             333.7±40            Echocardiography           BP↕, EF↕, IVS↓, LVMi↓
  Colao *et al*\[[@ref45]\]        2002   25                     Octreotide LAR   6                   20^e^             43.8±6             5.04±1.1          772±34               422.3±5.3           Echocardiography           HR↓, BP↕, EF↕, LVMi↓
  Lombardi *et al*\[[@ref32]\]     2002   19                     Lanreotide PR    6                   30^d^             37.9±7.5           5.7±2.5           143.8±21.9           36.4±17             Echocardiography           HR↓, BP↕, EF↕, IVS↓, LVMi↓, E/A↕
  Colao *et al*c\[[@ref47]\]       2003   10                     Octreotide LAR   12                  20^e^             90.9±22.8          68.1±11.4         714.7±61             614±71              Echocardiography           HR↕, BP↓,EF↑, LVMi↓
  Colao *et al*c\[[@ref47]\]       2003   12                     Octreotide LAR   12                  20^e^             68.1±11.4          4.5±0.6           614.6±71             272±18.8            Echocardiography           HR↕, BP↕, EF↑, LVMi↓
  Ronchi *et al*\[[@ref55]\]       2006   36                     OCT/LAN^f^       12                  10-30/60^e^       16.7±18            N/D               721.4±294            N/D                 None                       BP↕
  Colao *et al*\[[@ref56]\]        2008   56                     OCT/LAN^f^       12                  10-40/30-120^e^   52.9±44            1.3±0.6           712±225              N/D                 Echocardiography           HR↓, BP↓, EF↑, LVMi↓, E/A↑
  Delaroudis *et al*\[[@ref48]\]   2008   18                     Octreotide       6                   N/D               8.45               3.4               670±77               4473±58             None                       BP↕
  Colao *et al*\[[@ref57]\]        2009   45                     OCT/LAN^f^       60                  20-40/60-120^e^   44.2±39            0.88±0.4          664.9±241            185.5±57            Echocardiography           HR↓, BP↓, EF↑, LVMi↓, E/A↑
  Bogazzi *et al*\[[@ref52]\]      2010   14                     Lanreotide       6                   120e              6.4±9.9            4.3±5.5           725±212              401±161             CMRg                       EF↕, LVMi↓, RVMi↕
  Melmed *et al*\[[@ref53]\]       2010   99                     Lanreotide       12                  60-120^e^         19.8±29            6.6±19.7          735±240              376±172             Echocardiography           HR↓, LVEDV↓
  Annamalai *et al*\[[@ref54]\]    2013   30                     Lanreotide       6                   90-120^e^         21.43              N/D               N/D                  N/D                 Echocardiography           BP↕, LVMi↓
  Silva *et al*\[[@ref49]\]        2015   30                     Octreotide LAR   12                  20-30^e^          9.9±13.6           N/D               N/D                  N/D                 CMRg                       EF↑, IVS↕, LVEDVi↕, LVMi↕
  Warszawski *etal* \[[@ref35]\]   2016   28                     Octreotide LAR   12                  20-30^e^          4.9                N/D               318.4                N/D                 CMRg                       HR↓, EF↕, LVMi↕

^a^Data are based on mean ± SD but in some studies, not concluded SD, bDaily dose, cIn these studies, distinct populations have been analyzed separately, dAdministered every 10.15 days, eAdministered every 28 days, fOctreotide lAR in some patients and Lanreotide in others, gCardiac Magnetic Resonance Imaging, N/D: Not defined ↑: Significantly Increased, ↓: Significantly Decreased, ↕: Not Significant Change

Quality assessment {#sec2-4}
------------------

The methodological quality of the reviewed articles was measured using a scale of 11 items moderated from previous studies.\[[@ref36]\] This scale focused on reporting quality (4 items) and study quality (7 items). The items were identified as positive, negative, or not sufficiently defined. The total score for "reporting quality" and "study quality" was calculated using the sum of all positive scores for each study. For negative or not sufficiently defined items, no score was taken. The score of each study was to make it possible to compare to the percentage. Therefore, a higher percentage meant a higher reading quality. Based on the quality of the study, the articles were categorized according to the midterm considerations into high- and low-quality studies. Studies that were potentially eligible were further assessed in detail by retrieving full-length articles. As a second step, references cited in selected literature, in addition to those in relevant meta-analysis published in the last 10 years, were reviewed to identify additional potential studies for inclusion. When disagreement about inclusion or exclusion of specific studies occurred, all authors met to review and reach consensus. We could not conduct meta-analysis because of the considerable heterogeneity of the data including study design, patient population, and study duration.

RESULTS {#sec1-3}
=======

Study selection {#sec2-5}
---------------

The search strategy and stepwise results of the literature review are shown in [Figure 1](#F1){ref-type="fig"}.

![The search strategy and stepwise results of the literature review](JRMS-24-29-g001){#F1}

A literature search was conducted in MEDLINE (OVID), EMBase, Cochrane, and ISI Web of Science for citations published until April 30, 2018. A total of 38 articles were related to treatment with first-generation SSAs (octreotide or lanreotide) and CV effects. Of these, 24 articles met all inclusion criteria and included a total of 558 patients. In each of these studies, references cited within the articles and relevant meta-analysis studies were reviewed to determine the compliance with all criteria.\[[@ref30]\]

Study characteristics and results {#sec2-6}
---------------------------------

Characteristics of the 24 selected studies published between 1989 and 2016 are shown in [Table 1](#T1){ref-type="table"}. Of these, fifteen studies\[[@ref29][@ref35][@ref37][@ref38][@ref39][@ref40][@ref41][@ref42][@ref43][@ref44][@ref45][@ref46][@ref47][@ref48][@ref49]\] evaluated the impact of octreotide on cardiac parameters and BP, 6 studies\[[@ref32][@ref50][@ref51][@ref52][@ref53][@ref54]\] evaluated lanreotide, and 3 studies\[[@ref55][@ref56][@ref57]\] evaluated both octreotide and lanreotide. Treatment duration varied from day 1\[[@ref42]\] to 5 years;\[[@ref57]\] but in 19 studies, treatment duration was between 6 and 12 months. In 2007, Maison *et al*.\[[@ref30]\] conducted a meta-analysis on the impact of first-generation SSAs on CV parameters in patients with acromegaly. In the meta-analysis published by Maison *et al*.,\[[@ref30]\] 15 articles with 230 patients were evaluated, and thereafter, 9 studies\[[@ref35][@ref48][@ref49][@ref52][@ref53][@ref54][@ref55][@ref56][@ref57]\] with 328 patients were enrolled in our systematic review. The sample size of each of the studies evaluated by Maison *et al*.\[[@ref30]\] did not exceed 30 patients.

In 3 studies, cardiac parameters were assessed through CMR.\[[@ref35][@ref49][@ref52]\] Studies performed with dos Santos Silva *et al*.\[[@ref49]\] and Warszawski *et al*.\[[@ref35]\] used the same patient population; therefore, we extracted the effects on the HR from the study carried out by Silva and changes in EF and LVMi from the study carried out by Worszawski.

Changes in HR were investigated in 17 studies,\[[@ref29][@ref32][@ref35][@ref37][@ref39][@ref40][@ref41][@ref42][@ref43][@ref45][@ref46][@ref47][@ref50][@ref51][@ref53][@ref57]\] and 12\[[@ref29][@ref32][@ref35][@ref37][@ref39][@ref42][@ref43][@ref46][@ref53][@ref56][@ref57]\] of those (*n* = 350) indicated a significant reduction in HR.

In 18 studies (*n* = 380),\[[@ref29][@ref32][@ref37][@ref39][@ref40][@ref41][@ref42][@ref43][@ref45][@ref46][@ref47][@ref48][@ref50][@ref51][@ref54][@ref55][@ref56][@ref57]\] changes in BP were examined and 4 studies (*n* = 128)\[[@ref37][@ref48][@ref56][@ref57]\] reported that there was also a significant decrease in BP. In one study,\[[@ref56]\] only changes in diastolic BP were significant.

In 15 of 18 studies (*n* = 320),\[[@ref29][@ref32][@ref35][@ref37][@ref39][@ref40][@ref41][@ref42][@ref45][@ref47][@ref49][@ref50][@ref52][@ref54][@ref56][@ref57]\] LVMi changes evaluated were significant. However, it should be noted that in one study,\[[@ref54]\] including 15 men and 15 women, a significant reduction was seen only in men. In a survey of 14 patients conducted through CMR, there was no change regarding right ventricular mass index during 6 months of treatment.\[[@ref52]\]

LVEDD was analyzed in 7 of the studies (*n* = 78);\[[@ref39][@ref40][@ref41][@ref50][@ref51][@ref52]\] in 2 of which,\[[@ref50][@ref52]\] a significant reduction occurred in 27 patients. Of course, LVEDV was analyzed in 4 studies (*n* = 152),\[[@ref35][@ref49][@ref51][@ref52]\] of which 2 (*n* = 112)\[[@ref51][@ref53]\] showed a significant reduction.

In 18 publications (*n* = 365),\[[@ref29][@ref32][@ref35][@ref38][@ref39][@ref40][@ref41][@ref42][@ref43][@ref44][@ref45][@ref46][@ref47][@ref50][@ref51]\] changes in left ventricular ejection fraction (LVEF) were examined, 5 of which (*n* = 153)\[[@ref42][@ref46][@ref54][@ref56][@ref57]\] reported that both changes and effect size were significant. In 10 studies (*n* = 216),\[[@ref32][@ref38][@ref40][@ref42][@ref46][@ref50][@ref51][@ref52][@ref56][@ref57]\] E/A ratio was evaluated, and in 6 of them (*n* = 155),\[[@ref32][@ref40][@ref42][@ref52][@ref56][@ref57]\] improvement was statistically significant.

DISCUSSION {#sec1-4}
==========

This review suggests that first-generation SSAs have a beneficial effect on some cardiac parameters such as HR and LVMi. Therefore, at the outset, two points should be noted. First, the rare nature of acromegaly and patient heterogeneity contribute to a limitation in randomization. Furthermore, comorbidities such as HTN and insulin resistance can also confound the results independently, especially when concluding an overall result from all studies. Second, the absolute effect of these drugs on patients with impairment in a CV parameter can be more obvious and significantly different from those lacking this condition. In the following sections, we will discuss the impact of first-generation SSAs on different CV parameters.

Blood pressure {#sec2-7}
--------------

In patients with acromegaly, HTN is one of the most frequent CV complications.\[[@ref58]\] A mean prevalence of HTN in a meta-analysis of 18 studies was 35%, varying from 18% to 60%.\[[@ref59]\] Indeed, HTN is a determinant prognostic factor which increases mortality rates.\[[@ref10]\] When regarding the correlation between IGF-I levels and BP, results have been mixed.\[[@ref22][@ref60]\] Vitale *et al*.\[[@ref60]\] evaluated approximately 200 patients and showed that arterial hypertension predominantly involved diastolic BP and was less frequently related to IGF-I levels. However, recently, Schutte *et al*.\[[@ref61]\] evaluated more than 11000 patients and reported a positive relationship with BP when IGF-I levels were higher than normal values, but an inverse relationship when IGF-I levels were within normal values. Systemic HTN in acromegaly is multifactorial with several possible mechanisms.\[[@ref54][@ref59][@ref62][@ref63][@ref64]\] HTN can be controlled with an optimal treatment of acromegaly.\[[@ref22]\] However, the effect of biochemical control of acromegaly on HTN is not that straightforward; for example, Sardella *et al*.\[[@ref65]\] who reviewed a cohort of 200 acromegalic patients showed that optimal control of acromegaly did not influence BP. However, expression of somatostatin receptor subtypes has been seen in human vasculature, raising the probability of a direct effect of SSAs on the vascular system.\[[@ref22][@ref54][@ref66][@ref67]\] In addition, the effect of first-generation SSAs on glucose homeostasis may affect overall CV comorbidities.\[[@ref22][@ref57][@ref67]\]

In our systematic review, 3 of the studies (*n* = 72)\[[@ref37][@ref48][@ref57]\] reported a decrease in systolic and diastolic BP and 1 study\[[@ref56]\] reported a decrease in diastolic BP whereas in 14 studies (*n* = 356),\[[@ref29][@ref32][@ref39][@ref40][@ref41][@ref42][@ref43][@ref45][@ref46][@ref47][@ref50][@ref51][@ref55]\] there was no significant improvement in BP. Annamalai *et al*.\[[@ref54]\] reported a significant improvement in arterial stiffness (assessed by aortic pulse wave velocity evaluation) and endothelial cell function (assessed by flow-mediated dilation measurement) despite no improvement in BP after 6 months. They found that aortic pulse wave velocity (PWV) and flow-mediated dilation did not correlate with GH/IGF-I levels, which means that first-generation SSAs may have an independent beneficial effect on the vascular bed.\[[@ref54][@ref68][@ref69]\] In 2 studies by Colao *et al*. (*n* = 101),\[[@ref56][@ref57]\] significant improvement was observed only in diastolic BP. Interestingly, in a study by Delaroudis *et al*. (*n* = 18), a decrease in BP was recorded despite lack of biochemical control of acromegaly. At this point, it should be noted that of the 24 studies included in our systematic review, only Colao *et al*.\[[@ref57]\] evaluated hypertensive acromegalic patients, and among these patients, mean decrease in BP was \<10 mmHg. Results of an observational, retrospective, and multicenter study\[[@ref70]\] in 105 hypertensive patients showed that an improvement in HTN in patients with controlled acromegaly was only observed in those with severe HTN compared to those with mild HTN. The authors reported that in hypertensive patients, biochemical control of acromegaly leads to better control of hypertension independent of treatment methods. Indeed, in 7 studies\[[@ref29][@ref32][@ref40][@ref45][@ref47][@ref50][@ref51]\] included in our analysis, there were no changes in BP despite a decrease in myocardial thickness. Annamalai *et al*.\[[@ref54]\] reported that PWV improved irrespective of changes in BP and independent of changes in GH/IGF-I levels. In contrast, Cansu *et al*.,\[[@ref71]\] showed by analyzing 53 patients that there was no difference between patients with controlled or uncontrolled acromegaly. Finally, in a meta-analysis by Maison *et al*.,\[[@ref30]\] global effect size was not significant for BP. Therefore, in total, it seems that first-generation SSAs do not decrease BP significantly in normotensive patients, but we cannot rule out the beneficial effect of these drugs in hypertensive patients, and this concept should be evaluated in large randomized trials after adjustment for confounding variables.

Heart rate {#sec2-8}
----------

HR is modulated by the autonomic nervous system and is probably the best index of sympathovagal balance.\[[@ref17][@ref72]\] In patients suffering from acromegaly, a subclinical decompensated state might increase HR due to an enhanced hemodynamic response. Indeed, some degree of autonomic dysfunction has been reported in these patients.\[[@ref72][@ref73][@ref74]\] Biventricular hypertrophy, high HR, and increased cardiac output are characteristics of the early phase of acromegalic cardiomyopathy (hyperkinetic syndrome).\[[@ref73][@ref75]\] First-generation SSAs can decrease sinus rate, atrioventricular conduction, and propagation velocity in the cardiac conduction system.\[[@ref76]\] Some case reports showed asystole\[[@ref76]\] and severe bradycardia\[[@ref77]\] in less than a week of treatment with first-generation SSAs, but it seems that these drugs can decrease HR in the long term. Fatti *et al*. reported that first-generation SSAs reduced QT interval duration in acromegalic patients.\[[@ref78]\] Of the 24 studies included in our review, this parameter decreased in 12 studies (*n* = 350);\[[@ref29][@ref32][@ref35][@ref37][@ref38][@ref39][@ref42][@ref43][@ref46][@ref53][@ref56][@ref57]\] but in 6 studies (*n* = 71),\[[@ref29][@ref40][@ref41][@ref47][@ref50][@ref51]\] there was no decrease in HR despite decrease in GH/IGF-I levels. In the meta-analysis by Maison *et al*.,\[[@ref30]\] there was a significant decrease in HR and the weighted mean was −5.7 beat/min. Thereafter, all 4 studies\[[@ref35][@ref53][@ref56][@ref57]\] which evaluated HR reported a significant decrease in this parameter. In a study by Colao *et al*.,\[[@ref56]\] decrease in HR was only reported in the SSA versus surgical group, and this result supports the independent effect of first-generation SSAs on the vascular bed. In conclusion, first-generation SSAs decrease HR modestly, resulting at least theoretically in a decrease in myocardial oxygen consumption and arrhythmia burden, but an increase in diastolic filling time and coronary perfusion.

Left ventricle mass index {#sec2-9}
-------------------------

Acromegalic cardiomyopathy is characterized by concentric biventricular hypertrophy without cavity enlargement, mainly involving the LV. However, with time, cardiac chamber enlargement occurs and systolic heart failure develops.\[[@ref10][@ref74][@ref79]\] Severity of myocardial hypertrophy correlates with multiple factors such as patient age, disease duration, and presence of HTN, though not with IGF-I levels.\[[@ref80]\] Two-dimensional (2D) echocardiography is the most common method for the measurement of LV mass. However, this parameter is influenced by weight and height and is therefore commonly indexed to body surface area such as LVMi. Indeed, one of the most important limitations of 2D-echocardiography is reproducibility, and in the presence of abnormal left ventricular geometry due to asymmetrical hypertrophy, valvular heart disease, and previous myocardial infarction, LVMi calculation may not be accurate. Indeed, LV mass measurement by echocardiography is highly dependent on the change in intravascular volume.\[[@ref81][@ref82][@ref83]\] For this reason, LVMi calculation with CMR is more reliable than 2D-echocardiography.\[[@ref83]\] Indeed, CMR is considered the gold standard for quantifications of ventricular volume and mass.\[[@ref84]\] It has been shown that echocardiography significantly overestimates LV mass relative to CMR in the presence of left ventricular hypertrophy.\[[@ref82][@ref85][@ref86]\] However, Bogazzi *et al*.\[[@ref52]\] showed higher and dos Santos Silva *et al*.\[[@ref49]\] showed lower prevalence of LVH by CMR compared with 2D-echocardiography; therefore, by considering different cutoffs to define LVH, patients' heterogeneity, and basic characteristics, this disparity is evident and needs to be resolved by carrying out further large scale controlled trials. In our review, changes in LVMi, after treatment with first-generation SSAs, were evaluated in 17 studies (*n* = 358).\[[@ref29][@ref32][@ref35][@ref37][@ref39][@ref40][@ref41][@ref42][@ref44][@ref49][@ref50][@ref51][@ref52][@ref54][@ref57]\] In 15 studies (*n* = 320),\[[@ref29][@ref32][@ref37][@ref39][@ref40][@ref41][@ref44][@ref45][@ref47][@ref50][@ref51][@ref52][@ref54][@ref56][@ref57]\] treatment with SSAs contributed to a decrease in LVMi. In the 2 remaining studies, Giustina *et al*. (*n* = 10)\[[@ref42]\] reported no significant change after only 24-h treatment with octreotide infusion and Warszawski *et al*. (*n* = 28)\[[@ref35]\] showed no difference in LVMi measured by CMR after 12 months' treatment. However, in the latter study, only two patients had LVH from the beginning. Therefore, we cannot rule out the beneficial effect of SSAs on LVMi due to the results of these studies. The studies by Colao *et al*.\[[@ref29][@ref57]\] and Annamalai *et al*.\[[@ref54]\] reported no relationship between decreased LVMi, changes in BP and GH levels. The shortest time needed for LVMi decrease was reported to be approximately 7 days.\[[@ref39]\] In addition, the authors reported that a decrease in this parameter was only seen in patients with LVH. Recently, Volschan *et al*.\[[@ref34]\] reported that in patients with active acromegaly and high LVMi measured by 2D-echocardiography, there was no impairment in strain in comparison with the matched control group. This finding can be explained by the different pathophysiology of acromegalic cardiomyopathy in comparison with other types of cardiomyopathy.\[[@ref87][@ref88][@ref89][@ref90][@ref91]\] In conclusion, it seems that these drugs have a beneficial effect on patients with LVH irrespective of biochemical control of acromegaly. However, with the advent of new imaging modalities such as CMR and speckle tracking echocardiography, we need to carry out large scale prospective studies which will evaluate these changes with more sensitive and accurate technology than currently accepted as being the norm.

Left ventricular ejection fraction {#sec2-10}
----------------------------------

The LVEF remains the most frequently used method for the measurement of systolic function. It is one of the simplest diagnostic and prognostic parameters in CV medicine.\[[@ref85]\] In our review, increase of LVEF was reported in 5 studies (*n* = 153),\[[@ref42][@ref46][@ref49][@ref56][@ref57]\] while in 14 studies (*n* = 212),\[[@ref29][@ref32][@ref38][@ref39][@ref40][@ref41][@ref43][@ref44][@ref45][@ref46][@ref47][@ref50][@ref51][@ref52]\] treatment with these drugs did not contribute to an increase in LVEF. When using CMR, Bogazzi *et al*.\[[@ref52]\] showed no change after 6 months whereas dos Santos Silva *et al*.\[[@ref49]\] showed a significant increase in LVEF after 12 months. In a meta-analysis by Maison *et al*.,\[[@ref30]\] there is a trend toward an increase in LVEF, but globally no positive effect could be shown on fractional shortening and left ventricular end systolic diameter. In a study by Colao *et al*.,\[[@ref56]\] increase in LVEF was only reported in the SSA treated versus the surgical group; this result supports the independent effect of SSAs on cardiac function. Taking these facts into consideration, we cannot decide whether this information is beneficial for patients with reduced EF or not because we have been unable to extract the necessary information for confident prescription using these studies.

Left ventricular size {#sec2-11}
---------------------

Concentric hypertrophy is a common feature of acromegalic cardiomyopathy; this is why LV enlargement was seen only in advanced cardiomyopathy. Therefore, beneficial effects defined by an increase or a decrease in LV volume may vary depending on the stage of cardiomyopathy. In our systematic review, decrease of LVEDD in 2 studies (*n* = 27)\[[@ref50][@ref52]\] was reported, but in 5 studies (*n* = 51),\[[@ref38][@ref39][@ref40][@ref41][@ref51]\] treatment with these drugs did not contribute to a decrease in LVEDD. In addition, 2 studies (*n* = 112)\[[@ref51][@ref53]\] reported no significant changes in LVEDD. As mentioned before, CMR is considered to be the gold standard for quantifications of ventricular size.\[[@ref84]\] However, Bogazzi *et al*.\[[@ref52]\] showed a decrease in LVEDD and dos Santos Silva *et al*.\[[@ref49]\] showed no significant changes of LVEDD by CMR; therefore, this disparity is evident by considering patients' heterogeneity and basic characteristics and needs to be resolved by carrying out further large scale controlled trials.

E/A ratio {#sec2-12}
---------

The E/A ratio is defined as the ratio of the peak early (E) ventricular filling velocity to the peak late (A) ventricular filling velocity. It is one of the simple indexes used to assess the diastolic function of the LV.\[[@ref92][@ref93][@ref94]\] In a healthy heart, this ratio is usually between 1 and 2.\[[@ref93]\] In patients with Grade 1 diastolic dysfunction, this ratio decreases, but with the progression of the diastolic dysfunction and subsequent elevated left atrium pressure, this ratio increases by up to over one (termed pseudonormalization). Therefore, since this pattern of diastolic dysfunction can appear to be similar to the normal pattern, this parameter isolated can be misleading.\[[@ref92]\] In addition, this ratio depends on HR, preload alteration, patient\'s age, afterload, insulin resistance, and severity of mitral regurgitation. Considering the above-mentioned data, this parameter is not an accurate reflection of diastolic dysfunction, and we should interpret changes of this parameter only together with other diastolic parameters such as tissue Doppler and pulmonary venous pattern.\[[@ref92][@ref95][@ref96]\] In our systematic review, E/A ratio was assessed in 10 studies (*n* = 216),\[[@ref32][@ref38][@ref40][@ref42][@ref46][@ref50][@ref51][@ref52][@ref56][@ref57]\] and in six (*n* = 155),\[[@ref32][@ref40][@ref42][@ref52][@ref56][@ref57]\] this ratio increased. However, in the meta-analysis by Maison *et al*.,\[[@ref30]\] overall effect size was significant for E/A ratio, and in 3 studies\[[@ref52][@ref56][@ref57]\] performed thereafter, treatment with first-generation SSAs had a significant positive effect on E/A ratio. In the study by Colao *et al*.,\[[@ref56]\] increase in E/A ratio was only reported in the SSA treated versus the surgical group despite biochemical control in both groups. In a study by Boggazi *et al*. (*n* = 14),\[[@ref52]\] diastolic dysfunction was seen in 4 patients; but after 6 months of treatment, improvement in diastolic function was seen in only 1 patient. Therefore, due to the very low sample size, we cannot rely on these results. In conclusion, although first-generation SSAs can theoretically improve diastolic dysfunction with several mechanisms, any result achieved from a single parameter, such as the E/A ratio, should be concluded with caution.

CONCLUSION {#sec1-5}
==========

This systematic review suggests that first-generation SSAs have a beneficial effect on some cardiac parameters such as HR and LVMi. On the other hand, since not enough literature data exist, we were not able to detect sufficient evidence to draw firm conclusions with respect to the BP and other cardiac parameters such as EF, LV size, and E/A ratio. It is therefore recommended that endocrinologists and cardiologists continue to cooperate and maintain close dialogue to ensure optimal care for their patients.
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